




# SHINE Update

SHINE Medical Technologies | September 2019

CONFIDENTIAL: Property of SHINE Medical Technologies  
Not to be copied, used or disclosed for any reason.

# Mission

Dedicated to being the world leader in the safe, clean, affordable production of medical tracers and cancer treatment elements.



# Platform technology produces medical isotopes at a fraction of today's cost

Technology proven by US Laboratories and GE Healthcare




**ACCELERATOR  
(ELIMINATES REACTOR)**



**RE-USABLE  
LIQUID TARGET**



**SAFER  
70-80% LOWER COSTS  
1/100<sup>th</sup> WASTE**



# Signed customer contracts for over 10M doses





# U.S. Isotope Production Facility

- 91 acres in Janesville, Wisconsin
- High-specific activity Mo-99 without a reactor
- Capacity >4,000 6-day Ci/wk
- Xe-133, I-131, Lu-177, Sr-89, others
- 8 independent irradiation units
  - High reliability
  - Flexible production schedule
- Close to regional airport



<50,000

Square Feet

8

Accelerators

3

Independent  
Hot Cell Chains

>2/3

Annual U.S.  
Demand Met

# Building One: 1<sup>st</sup> building on the SHINE campus




- Construction complete Q1 2018
- First Production Unit accelerator demo first half of 2019
- Future use for employee training and technology development







# Full-Scale Accelerator System Demonstration





# Clearly defined path to market

Milestone	Timing
Demonstrate technology, sales viability	✓
Construction permit approval	✓
Major institutional investment (over \$300M raised to date)	✓
Full-scale accelerator demonstration	✓
Groundbreaking and start construction	✓
Submit Operating License application to NRC	✓
Operating license approval and first isotope production	2021
Phase I commercial operations: Mo-99 sales	2022
Sales of other isotopes begin (e.g. Xe-133, I-131, Lu-177)	2023
Largest global producer; start construction on European plant	2023

# Recent Developments

- November 2018 – \$150M Deerfield financing – Over \$300M raised to date
- May 2019 – Production facility groundbreaking
- May 2019 – IOCB Prague Lu-177 separation technology license agreement
- June 2019 – Full-scale accelerator operation demonstrated at Building One
- July 2019 – Operating License Application submitted to federal regulator
- August 2019 – Paul Ryan joins SHINE Board of Directors
- September 2019 – Excavation begins









# Current Activities/Next Steps

- Preparing for first concrete pour
- Negotiating additional supply agreements
- 100+ employees; rapid hiring on-going
- Lu-177 development
- First Mo-99 production 2021
- European facility site selection





# Questions?

